Navigation Links
Omeros to Present at the BioCentury NewsMakers Conference
Date:10/15/2010

SEATTLE, Oct. 15 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference on October 22, 2010 at 1:30 p.m. Eastern time in New York City. The presentation will be webcast. The live or archived webcast can be accessed on the "Events" page of the Company's website at www.omeros.com.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery(TM) platform, the most advanced of which is in a Phase 3 clinical program, and one from its Addiction program. Omeros may also have the near-term capability, through its GPCR program, to add wholly new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of antibody and small-molecule preclinical programs targeting inflammation and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Synapse Biomedical Inc. ( www.synapsebiomedical.com ) announced ... post-approval study of its NeuRx DPS® System for ... the FDA enrollment requirement was implanted over a ... NeuRx DPS®, which is the only medical device ... is a humanitarian device that obtained approval at ...
(Date:9/30/2014)... , Sept. 30, 2014 EXECUTIVE SUMMARY ... Industry Outlook to 2017 - Increasing Demand from ... analysis of the industry past, present and future ... Canada market with outlook to ... dietary supplements. Additionally the sub-segments of the industry, ...
(Date:9/30/2014)... DURHAM, N.C. , Sept. 30, 2014 /PRNewswire/ ... that Viztek LLC (Viztek), a leading provider of ... licensed HeartIT,s zero footprint patent portfolio. The licensed ... to provide access to diagnostic-quality medical images in ... part of the agreement, Viztek and its Subsidiaries ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 2North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 3
... 2011 Varian Medical Systems (NYSE: ... order from U.S. Customs and Border Protection (CBP) for multiple ... represents the company,s largest single order for Varian,s IntellX gantry ... border, scanning vehicles for both border security and manifest verification ...
... PITTSBURGH, Jan. 27, 2011 Mylan Inc. (Nasdaq: ... subsidiary Matrix Laboratories Limited has signed an agreement ... manufacture, market and distribute a generic version of ... pending its regulatory approval for the treatment of ...
Cached Medicine Technology:Varian Medical Systems' Security and Inspection Products Group Receives Largest Single Order for IntellX Systems 2Mylan's Matrix Obtains License for Promising HIV/AIDS Treatment 2
(Date:9/30/2014)... HealthDay Reporter , MONDAY, Sept. ... broad-spectrum antibiotics before the age of 2 may face ... new research suggests. Broad-spectrum antibiotics target a larger ... study. "It is a reason to think about ... picking," said lead researcher Dr. Charles Bailey, attending physician ...
(Date:9/30/2014)... Edward D. Buckingham, M.D., owner of ... approved to be a director of a fellowship for ... (AAFPRS) fellowship program. The announcement came last week from ... The Educational and Research Foundation for the AAFPRS fellowship ... the finest postgraduate program in the world for the ...
(Date:9/30/2014)... Gummy teeth treatment expert, Dr. ... dark gums. Dark gums are usually considered a cosmetic ... about their smiles. Dr. Farnoosh has pioneered a procedure ... of the few dental professionals nationwide offering black ... leaders, high-ranking officials and patients from all over the ...
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. ... supplements won,t prevent the return of a common type of ... In fact, 64.1 percent of those taking fish oil for ... over the course of 16 months, compared to 63.2 ... did not reduce the twin ills of inflammation or oxidative ...
(Date:9/30/2014)... 30, 2014 Lea Blackwell, M.D., a ... cancer patients a new, more practical and comfortable option ... undergo mastectomies, biopsies and lumpectomy surgeries use special bras ... after seeing her patients describe the bra as scratchy, ... a new bra in her spare time. , ...
Breaking Medicine News(10 mins):Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 3Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 2Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 3Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 2Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 3Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 3
... many as 10% of people of Asian descent, operations ... mathematical models that verified the cost effectiveness of hepatitis ... vaccinate millions of Asian and Pacific Islander adults in ... to a paper in a journal of the Institute ...
... (HealthDay News) -- In the days after they start ... bupropion or venlafaxine, nursing home residents are at significantly ... Researchers found the increased risk for falls also ... their current prescription. "Our results identify the days ...
... increasing globally. Requiring two doctors to agree that a ... baby, rather than just needing one opinion, providing internal ... and seeking support from local opinion leaders may reduce ... relaxation classes for women with a fear or anxiety ...
... spoils of war for returning veterans may include addictions, ... witnessed. Now a University of Houston joint study ... Development service looks to address these issues through the ... College of Social Work (GCSW) joins Baylor College of ...
... News) -- Depression rates are higher in richer countries ... who compared socioeconomic conditions with depression. About 121 ... quality of life by affecting their ability to ... suicide and causes 850,000 deaths every year. Detailed ...
... 26 (HealthDay News) -- A person,s brain works hard to ... people,s shoes, no matter how different they may be, a ... California found people automatically attempt to empathize -- even with ... people must use two separate regions of their brain. ...
Cached Medicine News:Health News:INFORMS study: OR models of hepatitis B prove decisive in treating millions in US, China 2Health News:INFORMS study: OR models of hepatitis B prove decisive in treating millions in US, China 3Health News:Certain Antidepressants Linked to Falls in Nursing Homes 2Health News:Local efforts can stem the increasing unnecessary cesarean sections 2Health News:Returning vets' alcohol abuse addressed in virtual reality study 2Health News:Depression Higher in Wealthier Nations 2Health News:Human Brains Wired to Empathize, Study Finds 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: